Apogem Capital LLC Prothena Corp Public LTD CO Transaction History

Apogem Capital LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $466,114 - $1.12 Million	-18,526 Reduced 45.08%	22,566 $1.37 Million
Q2 2022 Aug 15, 2022	SELL	$22.73 - $39.98 $14,615 - $25,707	-643 Reduced 1.54%	41,092 $1.12 Million
Q1 2022 May 16, 2022	BUY	$30.27 - $49.22 $257,991 - $419,502	8,523 Added 25.66%	41,735 $1.53 Million
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $352,165 - $612,673	8,363 Added 33.66%	33,212 $1.64 Million
Q3 2021 Nov 15, 2021	SELL	$48.2 - $78.89 $349,691 - $572,346	-7,255 Reduced 22.6%	24,849 $1.77 Million
Q2 2021 Aug 16, 2021	SELL	$21.63 - $57.65 $304,636 - $811,942	-14,084 Reduced 30.49%	32,104 $1.65 Million
Q1 2021 May 14, 2021	SELL	$11.0 - $28.24 $229,075 - $588,098	-20,825 Reduced 31.08%	46,188 $1.16 Million
Q4 2020 Feb 16, 2021	BUY	$10.12 - $13.94 $678,171 - $934,161	67,013 New	67,013 $805,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $641M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Apogem Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Apogem Capital LLC with notifications on news.